Search Form
First, enter a politician or zip code
Now, choose a category

Public Statements

Gingrey Bill Fast-Tracks New Drug Development

Press Release

Location: Washington, DC

As a result of the GAIN Act, legislation authored by Rep. Phil Gingrey, M.D., the FDA this week conferred special status to delafloxacin, a new drug being developed for use in hospitals as a "first-line" antibiotic. The bipartisan GAIN Act, signed into law in July, aims to spur development of new drugs to treat the growing number of "superbugs." It also streamlines and fast-tracks the FDA review process, ensuring patients have access to life-saving treatments. The drug is under development to treat lung infections, including pneumonia and bronchitis, and skin infections by Rib-X Pharmaceuticals.

"Fast-tracking drugs like delafloxacin will help decrease the risk of a nationwide, drug-resistant epidemic," said Rep. Gingrey. "As a physician for more than 30 years, I understand the critical need for new medical treatments. Because of the GAIN Act, today marks the first step in that direction. I look forward to the research and development of more drug-resistant antibiotics. "

In addition to protecting public health, the GAIN Act also seeks to stem the tide of drug developers and clinical trials from moving overseas.

Skip to top

Help us stay free for all your Fellow Americans

Just $5 from everyone reading this would do it.

Back to top